Alterations of biomarker profiles after neoadjuvant chemotherapy in breast cancer: tumor heterogeneity should be taken into consideration

Tumor biomarkers including estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and Ki-67 are routinely tested in breast cancer patients and their status guides clinical management and predicts prognosis. A few retrospective studies have suggested that...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Oncotarget
Prif Awduron: Zhou, Xingchen, Zhang, Junyong, Yun, Haiqin, Shi, Ranran, Wang, Yan, Wang, Wei, Lagercrantz, Svetlana Bajalica, Mu, Kun
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Impact Journals LLC 2015
Pynciau:
Clinical Research Paper
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4742218/
https://ncbi.nlm.nih.gov/pubmed/26384297
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg